Office of Technology Transfer: Technology Abstract
The inventors discovered a novel CPE splice variant designated CPE-deltaN and found its expression levels increase according to the presence of cancer and metastasis wherein this variant is upregulated in tumors and further increased in metastatic cancer. This data has been demonstrated both in vitro and in vivo experiments and in liver, breast, prostate, colon, and head and neck cancers. Metastatic liver cells treated with CPE-deltaN siRNA reversed the cells from being metastatic and arrested cells from further metastasis. Thus, this novel CPE isoform is a biomarker for predicting metastasis and its inhibitors have an enormous potential to increase patient survival. Applications:
The technology is currently in the pre-clinical stage of development. Market:
U.S. Provisional Application No. 61/080,508 filed 14 Jul 2008
Available for exclusive or non-exclusive licensing. Collaborative Research Opportunity: The National Institute of Child Health and Human Development, Laboratory of Development Neurobiology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method for Predicting and Detecting Tumor Metastasis. Please contact Joseph M. Conrad, LD, PhD, at 301-435-3107 or jmconrad@mail.nih.gov for more information.
Cancer -Therapeutics-Gene Therapy Cancer -Diagnostics Cancer -Therapeutics Cancer -Other
NIH Office of Technology Transfer 6011 Executive Blvd, Suite 325 Rockville, MD 20852-3804 Phone: (301)435-4633 Email: wongje@mail.nih.gov Fax: (301)402-0220 Web Ref: 1865 Last Updated On: 1/09 |